Serum and cerebrospinal fluid S100B concentrations in patients with neurocysticercosis
The clinical manifestations of neurocysticercosis (NC) are varied and depend on the number and location of cysts, as well as on the host immune response. Symptoms usually occur in NC when cysticerci enter a degenerative course associated with an inflammatory response. The expression of brain damage...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Associação Brasileira de Divulgação Científica
2006-01-01
|
| Series: | Brazilian Journal of Medical and Biological Research |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006000100015 |
| _version_ | 1828931841003880448 |
|---|---|
| author | J.E. Lima R. Walz A. Tort D. Souza L. Portela M.M. Bianchin O.M. Takayanagui J.P. Leite |
| author_facet | J.E. Lima R. Walz A. Tort D. Souza L. Portela M.M. Bianchin O.M. Takayanagui J.P. Leite |
| author_sort | J.E. Lima |
| collection | DOAJ |
| description | The clinical manifestations of neurocysticercosis (NC) are varied and depend on the number and location of cysts, as well as on the host immune response. Symptoms usually occur in NC when cysticerci enter a degenerative course associated with an inflammatory response. The expression of brain damage markers may be expected to increase during this phase. S100B is a calcium-binding protein produced and released predominantly by astrocytes that has been used as a marker of reactive gliosis and astrocytic death in many pathological conditions. The aim of the present study was to investigate the levels of S100B in patients in different phases of NC evolution. Cerebrospinal fluid and serum S100B concentrations were measured in 25 patients with NC: 14 patients with degenerative cysts (D), 8 patients with viable cysts (V) and 3 patients with inactive cysts. All NC patients, except 1, had five or less cysts. In most of them, symptoms had been present for at least 1 month before sample collection. Samples from 8 normal controls (C) were also assayed. The albumin quotient was used to estimate the blood-brain barrier permeability. There were no significant differences in serum (P = 0.5) or cerebrospinal fluid (P = 0.91) S100B levels among the V, D, and C groups. These findings suggest that parenchymal changes associated with a relatively small number of degenerating cysts probably have a negligible impact on glial tissue. |
| first_indexed | 2024-12-14T00:53:00Z |
| format | Article |
| id | doaj.art-5034ae3f575a4bc6b0ce7b5f4d01c274 |
| institution | Directory Open Access Journal |
| issn | 0100-879X 1414-431X |
| language | English |
| last_indexed | 2024-12-14T00:53:00Z |
| publishDate | 2006-01-01 |
| publisher | Associação Brasileira de Divulgação Científica |
| record_format | Article |
| series | Brazilian Journal of Medical and Biological Research |
| spelling | doaj.art-5034ae3f575a4bc6b0ce7b5f4d01c2742022-12-21T23:23:43ZengAssociação Brasileira de Divulgação CientíficaBrazilian Journal of Medical and Biological Research0100-879X1414-431X2006-01-0139112913510.1590/S0100-879X2006000100015Serum and cerebrospinal fluid S100B concentrations in patients with neurocysticercosisJ.E. LimaR. WalzA. TortD. SouzaL. PortelaM.M. BianchinO.M. TakayanaguiJ.P. LeiteThe clinical manifestations of neurocysticercosis (NC) are varied and depend on the number and location of cysts, as well as on the host immune response. Symptoms usually occur in NC when cysticerci enter a degenerative course associated with an inflammatory response. The expression of brain damage markers may be expected to increase during this phase. S100B is a calcium-binding protein produced and released predominantly by astrocytes that has been used as a marker of reactive gliosis and astrocytic death in many pathological conditions. The aim of the present study was to investigate the levels of S100B in patients in different phases of NC evolution. Cerebrospinal fluid and serum S100B concentrations were measured in 25 patients with NC: 14 patients with degenerative cysts (D), 8 patients with viable cysts (V) and 3 patients with inactive cysts. All NC patients, except 1, had five or less cysts. In most of them, symptoms had been present for at least 1 month before sample collection. Samples from 8 normal controls (C) were also assayed. The albumin quotient was used to estimate the blood-brain barrier permeability. There were no significant differences in serum (P = 0.5) or cerebrospinal fluid (P = 0.91) S100B levels among the V, D, and C groups. These findings suggest that parenchymal changes associated with a relatively small number of degenerating cysts probably have a negligible impact on glial tissue.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006000100015NeurocysticercosisS100BCerebrospinal fluidumin quotientGlial marker |
| spellingShingle | J.E. Lima R. Walz A. Tort D. Souza L. Portela M.M. Bianchin O.M. Takayanagui J.P. Leite Serum and cerebrospinal fluid S100B concentrations in patients with neurocysticercosis Brazilian Journal of Medical and Biological Research Neurocysticercosis S100B Cerebrospinal fluid umin quotient Glial marker |
| title | Serum and cerebrospinal fluid S100B concentrations in patients with neurocysticercosis |
| title_full | Serum and cerebrospinal fluid S100B concentrations in patients with neurocysticercosis |
| title_fullStr | Serum and cerebrospinal fluid S100B concentrations in patients with neurocysticercosis |
| title_full_unstemmed | Serum and cerebrospinal fluid S100B concentrations in patients with neurocysticercosis |
| title_short | Serum and cerebrospinal fluid S100B concentrations in patients with neurocysticercosis |
| title_sort | serum and cerebrospinal fluid s100b concentrations in patients with neurocysticercosis |
| topic | Neurocysticercosis S100B Cerebrospinal fluid umin quotient Glial marker |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006000100015 |
| work_keys_str_mv | AT jelima serumandcerebrospinalfluids100bconcentrationsinpatientswithneurocysticercosis AT rwalz serumandcerebrospinalfluids100bconcentrationsinpatientswithneurocysticercosis AT atort serumandcerebrospinalfluids100bconcentrationsinpatientswithneurocysticercosis AT dsouza serumandcerebrospinalfluids100bconcentrationsinpatientswithneurocysticercosis AT lportela serumandcerebrospinalfluids100bconcentrationsinpatientswithneurocysticercosis AT mmbianchin serumandcerebrospinalfluids100bconcentrationsinpatientswithneurocysticercosis AT omtakayanagui serumandcerebrospinalfluids100bconcentrationsinpatientswithneurocysticercosis AT jpleite serumandcerebrospinalfluids100bconcentrationsinpatientswithneurocysticercosis |